Improving muscle function in type 1 diabetes with resveratrol
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
EARLY_PHASE1 · Augusta University · NCT04449198
This study is testing if taking resveratrol for 12 weeks can help improve muscle function and lower heart disease risk in people with type 1 diabetes.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Augusta University (other) |
| Locations | 1 site (Augusta, Georgia) |
| Trial ID | NCT04449198 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate whether resveratrol supplementation for 12 weeks can enhance endothelin-B receptor function and mitochondrial function in skeletal muscle among individuals with type 1 diabetes. The researchers will utilize innovative, minimally invasive techniques such as intradermal microdialysis and near infrared spectroscopy to assess these functions. The central hypothesis is that increasing circulating Sirt1 through resveratrol will lead to improvements in both receptor and muscle function, potentially lowering cardiovascular disease risk in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are men and premenopausal women diagnosed with insulin-dependent type 1 diabetes.
Not a fit: Patients with uncontrolled diabetes, significant diabetic complications, or other serious health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve muscle function and reduce cardiovascular disease risk in patients with type 1 diabetes.
How similar studies have performed: While this approach is innovative, preliminary data suggest potential benefits, indicating that similar studies may have shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and premenopausal women * All races * Clinical diagnosis of insulin-dependent type 1 diabetes (patients only) Exclusion Criteria: * Clinical diagnosis of hepatic, cardiovascular, or renal disease * Uncontrolled diabetes (HbA1C \>12%) * Diabetic complications (i.e. neuropathy) * Uncontrolled hypertension (\>140/90 mm Hg on therapy) * Pregnancy * Use of vasoactive medications
Where this trial is running
Augusta, Georgia
- Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology — Augusta, Georgia, United States (RECRUITING)
Study contacts
- Study coordinator: Ryan A Harris, PhD, CEP
- Email: ryharris@augusta.edu
- Phone: 7067215998
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Type 1 Diabetes, diabetes, heart disease, muscle function, blood vessels